Home » Newsletters » BioWorld Science

BioWorld Science

June 13, 2000

View Archived Issues

Enzo Biochem reports significant progress for HIV gene medicine

Scotia reports improved complete tumor response rate with Foscan PDT

Novogen anticancer drug advances to phase Ib

Health Canada grants priority review to Prevnar

Onyx commences phase III clinical trial of CI-1042 to treat H&N cancer

Phase II cumulative-dose trial of MSI-albuterol in adults successfully completed

Icos and Texas Biotechnology enter joint venture to develop and commercialize endothelin antagonists

In vitro data support continued testing of AIDS vaccine in S. Africa

CLX-1100: a novel antiinflammatory agent produced by a Himalayan plant

Centaur describes new nitrone with potential in MS at Immunology 2000

VX-497: in vitro and in vivo findings on a selective, orally active IMPDH inhibitor

Further validation of NitroMed's approach to new drug candidates for GI diseases

ARGENT + Dimerizer Drugs results in sustained production of EPO in monkeys

Glaxo Wellcome's GI-262570 a success story, ADA participants told

Development of new formulation of erythropoietin halted

OSI crosslicenses gene transcription patent estate with Merck

GenStar's new Ad vector for hemophilia A proves safe and effective in murine model

News from ADA: Calyx completes phase Ib testing of plant extract

Axcan completes acquisition of worldwide Photofrin rights

Methods of diagnosing and treating breast cancer under scrutiny at Georgetown

U.S. scientists modify RNase A polypeptides to obtain selective cytotoxicity against KS cells

Cytokine production inhibitors described in patent literature by Novartis

PDE4-inhibitory respiratory therapeutics designed at Zambon

Recently issued patent covers potent and selective alpha1A-adrenoceptor antagonists from Merck

Japanese researchers discover new antiinflammatory substance

New GI therapeutics in development at Byk Gulden

BMS presents new IMP dehydrogenase inhibitors

Preparation and use of new thiazole antitumor agents acting on cdk/cyclin complexes

New long-acting basal insulin is at least as effective as NPH insulin, with less hypoglycemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...